サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1288861

がん支持療法薬の世界市場調査レポート-産業分析、規模、シェア、成長、動向、2023年から2030年までの予測

Global Cancer Supportive Care Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 99 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
がん支持療法薬の世界市場調査レポート-産業分析、規模、シェア、成長、動向、2023年から2030年までの予測
出版日: 2023年05月01日
発行: Value Market Research
ページ情報: 英文 99 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん支持療法薬の世界需要は、2023年から2030年の間に4.5%のCAGRで、2022年の1,921万米ドルから2030年には2,732万米ドル近くに達すると推定されています。

がん支持療法薬は、特定の臓器や細胞を保護することで、がん治療による有害な副作用を軽減するために使用される薬物です。これらの薬剤は、がん治療には使用されません。支持薬は、時に保護薬とも呼ばれます。がん支持療法に関与する主な薬物クラスには、貧血（CIA）に対するESA、好中球減少（CIN）に対するG-CSF、がんによる骨疾患に対するビスフォスフォネート、吐き気と嘔吐（CINV）に対する制吐薬、がん疼痛に対するNSAIDsなどがあります。がん治療薬の副作用は、主に薬剤の種類、投与量、患者の健康状態に左右されます。

市場力学：

世界のがん罹患率の上昇とがん治療に伴う多くの副作用が、予測期間中のがん支持療法薬市場を牽引する主要因となっています。それに加えて、バイオシミラーの普及が進み、効果的な治療法が利用できるようになったことも、がん支持療法薬市場の成長に拍車をかける要因となっています。また、ヘルスケアへの支出の増加や世界的に有益な医療改革が、市場成長にプラスの影響を与えています。さらに、従来のがん治療薬よりも副作用が少ない標的治療薬の技術的進歩により、今後数年間はより多くの需要が見込まれます。

本レポートでは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析について解説しています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。

さらに、これらのツールは、がん支持療法薬の世界市場における各アプリケーション/製品セグメントを包括的に評価するものでもあります。

地域別分析：

本セクションでは、北米、欧州、アジア太平洋、中南米、中東・アフリカにおけるがん支持療法薬市場の現在および将来の需要に重点を置いた地域別セグメンテーションを取り上げます。さらに、すべての著名な地域における個々のアプリケーションセグメントの需要に焦点を当てています。

また、この調査レポートは、市場の主要企業の包括的なプロファイルと、世界の競合情勢の詳細な見解もカバーしています。このセクションでは、主要なM&A、将来の能力、パートナーシップ、財務概要、共同研究、新製品の開発、新製品の発売など、さまざまな戦略的発展を含む競合情勢の全体像について解説しています。

カスタム要件がある場合、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズされたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • がん支持療法薬市場のハイライト
  • がん支持療法薬の世界市場スナップショット

第3章 がん支持療法薬- 産業分析

  • イントロダクション
  • がん支持療法薬市場の市場促進要因
  • がん支持療法薬市場の市場抑制要因
  • がん支持療法薬の市場機会
  • がん支持療法薬の市場動向
  • がん支持療法薬の市場に関するポーターのファイブフォース分析
  • がん支持療法薬市場の魅力度分析

第4章 バリューチェーン分析

  • がん支持療法薬のバリューチェーン分析
  • がん支持療法薬の原材料分析
    • 原材料のリスト
    • がん支持療法薬の原材料メーカーリスト
    • がん支持療法薬の主要原材料の価格動向
  • 潜在的なバイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネルの動向

第5章 COVID-19の発生による影響分析

第6章 がん支持療法薬の世界市場分析：治療クラス別

  • 治療クラス別の概要
  • 2015年～2018年の実績データ
  • がん支持療法薬の世界市場分析：治療クラス別
  • G-CSF（顆粒球コロニー刺激因子）の市場分析：地域別
  • ESA（赤血球造血刺激因子）の市場分析：地域別
  • 抗化粧品の市場分析：地域別
  • ビスホスホネートの市場分析：地域別
  • オピオイドの市場分析：地域別
  • 非ステロイド性抗炎症薬（NSAIDs）の市場分析：地域別

第7章 がん支持療法薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の販売分析
    • 概要と実績データ
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の販売分析
    • 概要と実績データ
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他
  • アジア太平洋地域の販売分析
    • 概要と実績データ
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他
  • ラテンアメリカの販売分析
    • 概要と実績データ
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他
  • 中東・アフリカ地域の販売分析
    • 概要と実績データ
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • UAE
    • イスラエル
    • 南アフリカ
    • その他

第8章 がん支持療法薬の企業の競合情勢

  • がん支持療法薬の市場競争
  • 提携・協業・合意
  • 合併・買収
  • 新製品発売
  • その他の開発

第9章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Amgen Inc.
    • 企業概要
    • 製品紹介
    • 最近の開発状況
  • Merck & Co.
    • 会社概要
    • 製品紹介
    • 最近の開発状況
  • Johnson & Johnson Services, Inc.
    • 会社概要
    • 製品情報
    • 最近の開発状況
  • Heron Theovartis
    • 会社概要
    • 製品情報
    • 最近の開発状況
  • Novartis AG
    • 会社概要
    • 製品情報
    • 最近の開発状況
  • GlaxoSmithKline plc（GSK）
    • 会社概要
    • 製品情報
    • 最近の開発状況
  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 製品情報
    • 最近の開発状況
  • Helsinn Healthcare SA
    • 会社概要
    • 製品情報
    • 最近の動向

企業プロファイルでは、財務内容や最近の開発状況については、入手可能な情報に基づいており、非公開会社の場合は掲載されていない場合があります。

図表

LIST OF TABLES

  • Global Cancer Supportive Care Drugs Market Snapshot
  • Drivers of The Global Cancer Supportive Care Drugs Market Impact Analysis
  • Restraints of The Global Cancer Supportive Care Drugs Market Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Global Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Historic Data 2015-2018
  • Global Cancer Supportive Care Drugs Market Analysis in G-CSFs (Granulocyte-colony Stimulating Factors) by Geography ( USD MN)
  • Global Cancer Supportive Care Drugs Market Analysis in ESAs (Erythropoiesis Stimulating Agents) by Geography ( USD MN)
  • Global Cancer Supportive Care Drugs Market Analysis in Anti-Emetics by Geography ( USD MN)
  • Global Cancer Supportive Care Drugs Market Analysis in Bisphosphonates by Geography ( USD MN)
  • Global Cancer Supportive Care Drugs Market Analysis in Opioids by Geography ( USD MN)
  • Global Cancer Supportive Care Drugs Market Analysis in (Non Steroidal Anti-Inflammatory Drugs) NSAIDs by Geography ( USD MN)
  • Global Cancer Supportive Care Drugs Market by Geography ( USD MN)
  • Historic Data 2015-2018
  • North America Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • North America Cancer Supportive Care Drugs Market Estimate by Country ( USD MN)
  • United State Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Canada Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Mexico Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Europe Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Europe Cancer Supportive Care Drugs Market Estimate by Country ( USD MN)
  • United Kingdom Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • France Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Germany Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Italy Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Russia Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Spain Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Rest of Europe Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Asia Pacific Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Asia Pacific Cancer Supportive Care Drugs Market Estimate by Country ( USD MN)
  • China Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Japan Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • India Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • South Korea Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Australia Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Rest of Asia Pacific Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Latin America Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Latin America Cancer Supportive Care Drugs Market Estimate by Country ( USD MN)
  • Brazil Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Argentina Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Peru Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Chile Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Rest of Latin America Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Middle East & Africa Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Middle East & Africa Cancer Supportive Care Drugs Market Estimate by Country ( USD MN)
  • Saudi Arabia Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • UAE Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Israel Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • South Africa Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Rest of Middle East and Africa Cancer Supportive Care Drugs Market Analysis by Therapeutic Class ( USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisiton

LIST OF FIGURES

  • Research Scope of Cancer Supportive Care Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Cancer Supportive Care Drugs Market Size, by Region (2019)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Therapeutic Class
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Cancer Supportive Care Drugs Market Analysis by Therapeutic Class
  • Global Cancer Supportive Care Drugs Market Analysis in G-CSFs (Granulocyte-colony Stimulating Factors) by Region
  • Global Cancer Supportive Care Drugs Market Analysis in ESAs (Erythropoiesis Stimulating Agents) by Region
  • Global Cancer Supportive Care Drugs Market Analysis in Anti-Emetics by Region
  • Global Cancer Supportive Care Drugs Market Analysis in Bisphosphonates by Region
  • Global Cancer Supportive Care Drugs Market Analysis in Opioids by Region
  • Global Cancer Supportive Care Drugs Market Analysis in (Non Steroidal Anti-Inflammatory Drugs) NSAIDs by Region
  • Global Cancer Supportive Care Drugs Market by Revenue
  • North America Cancer Supportive Care Drugs Market by Revenue
  • Europe Cancer Supportive Care Drugs Market by Revenue
  • Asia Pacific Cancer Supportive Care Drugs Market by Revenue
  • Latin America Cancer Supportive Care Drugs Market by Revenue
  • Middle East & Africa Cancer Supportive Care Drugs Market by Revenue
  • Recent Development in Cancer Supportive Care Drugs Industry
  • Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR11213519

The global demand for Cancer Supportive Care Drugs Market is presumed to reach the valuation of nearly USD 27.32 MN by 2030 from USD 19.21 MN in 2022 with a CAGR of 4.5% during the period of 2023-2030.

Cancer care supportive drugs are those drugs that are used to reduce the injurious side effects of cancer treatment by protecting specific organs or cells. These drugs are not used for cancer treatment. Supportive drugs are sometimes also called as protective drugs. The major drug classes involved in cancer supportive care include ESAs for the treatment of Anemia (CIA), G-CSFs for neutropenia (CIN), bisphosphonates for cancer-induced bone diseases, antiemetics for nausea and vomiting (CINV), and NSAIDs for treating cancer pain. The side effects of cancer supportive drugs will depend primarily on: drug type, the dose given, and the overall health of the patients.

Market Dynamics:

The increasing prevalence of cancer globally and many side effects associated with cancer treatment are the major factors driving the cancer supportive care drug market over the forecast time frame. In addition to that, increasing uptake of biosimilars and the availability of effective treatment methods are other factors that add fuel to the growth of the cancer supportive care drugs market. Also, rising expenditure on healthcare and beneficial healthcare reforms worldwide are positively impacting market growth. Moreover, the technological advancements in targeted therapy drugs, which have lesser side effects than traditional cancer therapy drugs, is anticipated to give rise to more demand in the coming years.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each application/product segment in the global market of cancer supportive care drugs.

Market Segmentation:

The entire cancer supportive care drugs market has been sub-categorized into therapeutic class. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.

By Therapeutic Class

  • G-CSFs (Granulocyte-colony Stimulating Factors)
  • ESAs (Erythropoiesis Stimulating Agents)
  • Anti-Emetics
  • Bisphosphonates
  • Opioids
  • (Non Steroidal Anti-Inflammatory Drugs) NSAIDs

Regional Analysis:

This section covers regional segmentation which accentuates on current and future demand for cancer supportive care drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cancer supportive care drugs market include Amgen Inc, Merck & Co. Inc., Johnson & Johnson Services Inc., Heron Therapeutics Inc., Novartis AG, GlaxoSmithKline plc (GSK), F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Cancer Supportive Care Drugs Market
  • 2.2. Global Cancer Supportive Care Drugs Market Snapshot

3 . CANCER SUPPORTIVE CARE DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction
  • 3.2. Market Drivers of Cancer Supportive Care Drugs Market
  • 3.3. Market Restraints of Cancer Supportive Care Drugs Market
  • 3.4. Opportunities of Cancer Supportive Care Drugs Market
  • 3.5. Trends of Cancer Supportive Care Drugs Market
  • 3.6. Porter's Five Force Analysis of Cancer Supportive Care Drugs Market
  • 3.7. Cancer Supportive Care Drugs Market Attractiveness Analysis
    • 3.7.1 Market Attractive Analysis by Therapeutic Class
    • 3.7.2 Market Attractive Analysis by Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Cancer Supportive Care Drugs Value Chain Analysis
  • 4.2. Cancer Supportive Care Drugs Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Cancer Supportive Care Drugs Raw Material Manufactures List
    • 4.2.3. Price Trend of Cancer Supportive Care Drugs Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET ANALYSIS BY THERAPEUTIC CLASS

  • 6.1 Overview by Therapeutic Class
  • 6.2 Historical Data 2015-2018
  • 6.3 Global Cancer Supportive Care Drugs Market Analysis by Therapeutic Class
  • 6.4 Market Analysis of G-CSFs (Granulocyte-colony Stimulating Factors) by Regions
  • 6.6 Market Analysis of ESAs (Erythropoiesis Stimulating Agents) by Regions
  • 6.5 Market Analysis of Anti-Emetics by Regions
  • 6.7 Market Analysis of Bisphosphonates by Regions
  • 6.8 Market Analysis of Opioids by Regions
  • 6.9 Market Analysis of (Non Steroidal Anti-Inflammatory Drugs) NSAIDs by Regions

7 . GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America
    • 7.3.1. Overview and Historic Data
    • 7.3.2. North America Cancer Supportive Care Drugs Market Estimate By Market Segment
    • 7.3.3. North America Cancer Supportive Care Drugs Market Estimate By Country
    • 7.3.4. United State
    • 7.3.5. Canada
    • 7.3.6. Mexico
  • 7.4. Europe
    • 7.4.1. Overview and Historic Data
    • 7.4.2. Europe Cancer Supportive Care Drugs Market Estimate by Market Segment
    • 7.4.3. Europe Cancer Supportive Care Drugs Market Estimate by Country
    • 7.4.4. United Kingdom
    • 7.4.5. France
    • 7.4.6. Germany
    • 7.4.7. Italy
    • 7.4.8. Russia
    • 7.4.9. Rest Of Europe
  • 7.5. Asia Pacific
    • 7.5.1. Overview and Historic Data
    • 7.5.2. Asia Pacific Cancer Supportive Care Drugs Market Estimate by Market Segment
    • 7.5.3. Asia Pacific Cancer Supportive Care Drugs Market Estimate by Country
    • 7.5.4. China
    • 7.5.5. India
    • 7.5.6. Japan
    • 7.5.7. South Korea
    • 7.5.8. Australia
    • 7.5.9. Rest Of Asia Pacific
  • 7.6. Latin America
    • 7.6.1. Overview and Historic Data
    • 7.6.2. Latin America Cancer Supportive Care Drugs Market Estimate by Market Segment
    • 7.6.3. Latin America Cancer Supportive Care Drugs Market Estimate by Country
    • 7.6.4. Brazil
    • 7.6.5. Argentina
    • 7.6.6. Peru
    • 7.6.7. Chile
    • 7.6.8. Rest of Latin America
  • 7.7. Middle East & Africa
    • 7.7.1. Overview and Historic Data
    • 7.7.2. Middle East & Africa Cancer Supportive Care Drugs Market Estimate by Market Segment
    • 7.7.3. Middle East & Africa Cancer Supportive Care Drugs Market Estimate by Country
    • 7.7.4. Saudi Arabia
    • 7.7.5. UAE
    • 7.7.6. Israel
    • 7.7.7. South Africa
    • 7.7.8. Rest Of Middle East And Africa

8 . COMPETITIVE LANDSCAPE OF THE CANCER SUPPORTIVE CARE DRUGS COMPANIES

  • 8.1. Cancer Supportive Care Drugs Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9 . COMPANY PROFILES OF CANCER SUPPORTIVE CARE DRUGS INDUSTRY

  • 9.1. Company Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Amgen Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financials
    • 9.3.3. Products
    • 9.3.4. Recent Developments
  • 9.4. Merck & Co.
    • 9.4.1. Company Overview
    • 9.4.2. Financials
    • 9.4.3. Products
    • 9.4.4. Recent Developments
  • 9.5. Johnson & Johnson Services, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financials
    • 9.5.3. Products
    • 9.5.4. Recent Developments
  • 9.6. Heron Theovartis
    • 9.6.1. Company Overview
    • 9.6.2. Financials
    • 9.6.3. Products
    • 9.6.4. Recent Developments
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Financials
    • 9.7.3. Products
    • 9.7.4. Recent Developments
  • 9.8. GlaxoSmithKline plc (GSK)
    • 9.8.1. Company Overview
    • 9.8.2. Financials
    • 9.8.3. Products
    • 9.8.4. Recent Developments
  • 9.9. F. Hoffmann-La Roche Ltd.
    • 9.9.1. Company Overview
    • 9.9.2. Financials
    • 9.9.3. Products
    • 9.9.4. Recent Developments
  • 9.10. Helsinn Healthcare SA
    • 9.10.1. Company Overview
    • 9.10.2. Financials
    • 9.10.3. Products
    • 9.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies